Full-Time

Business Development Associate : Pharmaceutical Development

D&M

Posted on 12/13/2025

Deadline 3/2/26
PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Bedford, NH, USA

In Person

Category
Business & Strategy (1)
Required Skills
Salesforce
Requirements
  • Bachelor’s Degree or higher in Pharmaceutical Sciences, Chemistry, or closely related field
  • Early-stage development and drug product manufacturing experience
  • Experience writing highly technical proposals
  • Strong interpersonal, communication, and organization skills
  • Proficiency with MS Office suite applications
  • Preferred proficiency with Salesforce.com or similar Customer Relationship Management tool
  • Drug product development and manufacturing experience
  • Ability to write highly technical proposals
  • Strong business acumen and problem-solving skills
  • Excellent planning and organizational skills
  • Ability to work in a fast-paced, cross-functional team
  • Superior verbal and written communication skills with both internal and external customers
Responsibilities
  • Responsible for writing high-quality proposals for including but not limited to Early-Stage Development.
  • Interact with Business Development (BD) team and external customers on Requests for Proposals (RFPs)
  • Leads and/or supports meetings with internal departments and external clients to discuss expectations associated with Proposals, revisions to proposals, and Change Orders.
  • Coordinates with Business Development and/or Project Management to schedule Subject Matter Expert (SME) meetings for RFQ reviews
  • Responsible for working with key stakeholders (Subject Matter Experts (SMEs), Project Managers, Business Development, etc.) to clearly define project scope, strategy, resource requirements, timelines, deliverables, and pricing
  • Prepare detailed project proposals, including supporting materials such as cost workbooks and high-level Gantt charts
  • Participates in peer review of proposals to support the Business Operations team
  • Participates in the development and implementation of new approaches, procedures, and processes to optimize and harmonize business processes across business segments
  • Acquires and maintains an in-depth knowledge of the organization’s areas of expertise and services for appropriate cross-sell opportunities to existing clients.
  • Collaborates with Subject Matter Experts (SME) to gather supporting information to be captured within Proposals.
  • Works with Sales, Project Management, and external customers to resolve issues associated with Proposals or Change Orders.
  • Assists in the development and implementation of Proposals and Change Orders where appropriate in accordance with sales objectives
  • Acts as a liaison between Project Management and Business Development Managers to support the transition of awarded Proposals into Project Management teams.
  • Supports the development of project timelines utilized within Proposals where appropriate.
  • Proactively identify, resolve, and escalate issues that may jeopardize Proposal/Change Order on-time completion
  • Trains new Business Development Associates hires on how to review, interpret, and utilize information provided within Request for Quotes (RFQs) and study protocols submitted by Project Management to draft Proposals submitted to customers.
  • Proactive in asking questions to obtain answers, collecting business process information, and working with others in a positive and collaborative manner.
  • Manages and prioritizes competing requests for multiple parties to ensure all tasks are completed.
  • Possesses the ability to solve complex problems with minimal guidance.
  • As required, participates in drafting Change Orders, Proposals, and revisions to Proposals.
  • Supports implementation of global proposal harmonization initiatives, including but not limited to developing change management and implementation plans for new or revised procedures.
  • Responsible for reporting Key Performance Indicators (metrics) on a weekly and monthly basis where applicable
  • Knowledge of and adherence to all appropriate PCI policies, procedures, and rules.
Desired Qualifications
  • Previous work experience is not essential but experience of proposals writing would be an advantage
  • Knowledge of CDMO market pricing and conditions
  • Experience with Service Agreements
  • Proven experience in strategic pricing and planning

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 surge drives demand for PCI's prefilled syringes and autoinjectors.
  • Oncology-CNS pipelines favor PCI's patient-centric drug-device combinations.
  • Bain Capital's $10B valuation fuels $1B capacity expansions through 2028.

What critics are saying

  • San Diego isolator line delays to H1 2028 cede contracts to Lonza.
  • Novo Nordisk's Catalent acquisition slashes external CDMO fill-finish availability.
  • PE backers force divestitures if biotech funding dries post-2025.

What makes PCI Pharma Services unique

  • PCI integrates sterile fill-finish with drug-device assembly for end-to-end injectables.
  • Ajinomoto Althea acquisition adds rare US high-potent ADC sterile filling expertise.
  • AVI systems inspect 75 million vials annually, scaling quality without bottlenecks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.

INACTIVE